Therapeutic monitoring and evaluating full elimination of the drug (eg, toxicity, pregnancy).
High Performance Liquid Chromatography/Mass Spectrometry
Sun, Wed, Fri
New York DOH Approval Status
Timing of specimen collection: Predose (trough). Obtain specimen 12 - 24 hours after last dose.
Plain red. Also acceptable: Lavender (EDTA), pink (K2EDTA), green (sodium heparin), or gray (sodium fluoride).
Separate from cells within 2 hours of draw. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.2 mL)
Refrigerated. Also acceptable: Room temperature or frozen.
Whole blood. Potassium oxalate or separator tubes.
Ambient: 7 days; Refrigerated: 17 days; Frozen: 90 days
|Therapeutic Range||Greater than 40.000 µg/mL|
|Toxic Level||Not well established.|
Therapeutic and toxic ranges are not well established. Concentrations greater than 40.000 µg/mL tend to correlate with improved patient outcome. A proposed therapeutic range is 50.000 - 100.000 µg/mL. Adverse reactions to Leflunomide, such as diarrhea, hypertension, and liver toxicity, do not correlate well with serum drug concentrations. Leflunomide has a potential risk for teratogenesis. For women being treated with Leflunomide who desire to become pregnant, enhanced drug elimination should be performed until plasma teriflunomide concentrations are lower than 0.020 µg/mL on two separate tests taken at least 14 days apart.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|2007461||Leflunomide Metabolite, Serum/Plasma||44828-2|
- Arava® (Leflunomide (Teriflunomide), Serum or Plasma)
- leflunomide blood concentration